Home | FCA & regulatory news | British English edition
Trade Hub UK

Independent coverage of UK markets, FCA policy and institutional trading
AD CME Group Education AD Bank of England Statistics AD Investing.com Markets AD LSEG Data
City & Markets

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

City noticeboard, Trade Hub UK (2026-10-02): Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. Primary source: original at CNBC Top News (cnbc.com).

By CNBC Top News

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Read at source

Read also
  1. Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
  2. Nike shares plummet 10% after weak revenue outlook and layoff plans underway
  3. Men are losing ground in the labor market. Here's why
  4. How AI is redefining Wall Street jobs — and boosting demand for this new 'hottest skill' by 1,721%
  5. The secret signs the bond sell-off might be ending

Source: CNBC Top News